Replies to post #60929 on Biotech Values

[DewDiligence]

My guess is either AHA (Nov 8-12) or ASH (Dec 9-12).

[DewDiligence]

MNTA Announces M118 Data Presentations at World Conference on Clinical Pharmacology and Therapeutics

[The two phase-1 presentations are: i) a drug-interaction study of M118, aspirin, and Plavix; and ii) an ascending-dose study with subcutaneous administration (#msg-19617749). These will be the first reported data on the sub-Q formulation of M118; the phase-2a study in progress in stable angina uses the infusional formulation.]

http://biz.yahoo.com/pz/080725/147183.html

›Friday July 25, 2:18 pm ET

CAMBRIDGE, Mass., July 25, 2008 (PRIME NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NasdaqGM: MNTA ), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that clinical data for its rationally engineered anticoagulant, M118, will be presented at the upcoming IXth World Conference on Clinical Pharmacology and Therapeutics Meeting. The meeting will be held July 27 to August 1, 2008, in Quebec City, Quebec.

The following two posters will be presented:

``Lack of Drug-Drug Interactions with M118, a Novel, Rationally Engineered Low Molecular Weight Heparin, When Co-Administered with Multiple Doses of Aspirin and Clopidogrel'' (abstract #033).

-- Poster Session: Monday, July 28, 2008 from 12:15 - 14:00.

``Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of M118, a Novel Rationally Engineered Low Molecular Weight Heparin Given as a Subcutaneous Injection in a Rising Dose Cohort Regimen in Healthy Subjects'' (abstract #025).

-- Poster Session: Tuesday, July 29, 2008 from 12:15 - 14:00.‹